Activation of oncogenic KRAS in PAAD is associated with the occurrence and progression of tumors reportedly in several aspects, including the deregulation of key signal transduction pathways, metabolic changes, metastasis, and drug resistance (Mann et al. 2016). This evidence concerns the gene KRAS and pancreatic adenocarcinoma.